↓ Skip to main content

A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial

Overview of attention for article published in Journal of Infection, May 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

policy
1 policy source
twitter
1 X user
patent
1 patent

Readers on

mendeley
83 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial
Published in
Journal of Infection, May 2015
DOI 10.1016/j.jinf.2015.05.006
Pubmed ID
Authors
Abstract

Outer membrane vesicle (OMV) vaccines are used against outbreaks of capsular group B Neisseria meningitidis (MenB) caused by strains expressing particular PorA outer membrane proteins (OMP). Ferric enterobactin receptor (FetA) is another variable OMP that induces type-specific bactericidal antibodies, and the combination of judiciously chosen PorA and FetA variants in vaccine formulations is a potential approach to broaden protection of such vaccines. The OMV vaccine MenPF-1 was generated by genetically modifying N. meningitidis strain 44/76 to constitutively express FetA. Three doses of 25μg or 50μg of MenPF-1 were delivered intramuscularly to 52 healthy adults. MenPF-1 was safe and well tolerated. Immunogenicity was measured by serum bactericidal assay (SBA) against wild-type and isogenic mutant strains. After 3 doses, the proportion of volunteers with SBA titres ≥ 1:4 (the putative protective titre) was 98% for the wild-type strain, and 77% for the strain 44/76 FetAonPorAoff compared to 51% in the strain 44/76 FetAoffPorAoff, demonstrating that vaccination with MenPF-1 simultaneously induced FetA and PorA bactericidal antibodies. This study provides a proof-of-concept for generating bactericidal antibodies against FetA after OMV vaccination in humans. Prevalence-based choice of PorA and FetA types can be used to formulate a vaccine for broad protection against MenB disease.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Netherlands 1 1%
United Kingdom 1 1%
Unknown 81 98%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Student > Bachelor 15 18%
Researcher 11 13%
Student > Ph. D. Student 10 12%
Student > Master 7 8%
Professor 3 4%
Other 7 8%
Unknown 30 36%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 12 14%
Biochemistry, Genetics and Molecular Biology 9 11%
Agricultural and Biological Sciences 8 10%
Immunology and Microbiology 8 10%
Nursing and Health Professions 3 4%
Other 10 12%
Unknown 33 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2022.
All research outputs
#6,130,449
of 31,660,612 outputs
Outputs from Journal of Infection
#1,120
of 3,627 outputs
Outputs of similar age
#61,605
of 295,770 outputs
Outputs of similar age from Journal of Infection
#7
of 37 outputs
Altmetric has tracked 31,660,612 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,627 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 295,770 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.